SleepRes said it has received FDA clearance for the Kricket PAP device, powered by Kairos Positive Airway Pressure (KPAP) for the treatment of obstructive sleep apnea (OSA).
The Kricket PAP device features proprietary KPAP technology, designed to dynamically adapt pressure delivery throughout the breathing cycle, rather than maintaining a constant, fixed pressure like traditional CPAP devices. The design is aimed at reducing unnecessary pressure, which may minimize discomfort, alleviate common side effects, and improve tolerance during sleep. The device includes the KPAP algorithm, as well as traditional CPAP and automatic PAP therapy modes.
SleepRes plans to commercially launch Kricket in the first half of 2026. The company is actively preparing to scale manufacturing, developing clinical partnerships, and providing education on KPAP ahead of launch.
“FDA clearance of Kricket marks a pivotal moment for patient care in sleep medicine,” said SleepRes CEO John Lipman in a statement. “It validates the innovation behind our technology and moves us another step closer to our mission of improving outcomes for people living with sleep apnea.”
